The natural history and treatment outcome of blast phase BCR-ABL(−) myeloproliferative neoplasms

We analyzed the outcomes of 74 patients diagnosed with BCR-ABL(−) myeloproliferative neoplasms in blast phase receiving induction chemotherapy (55%), low-intensity therapy (16%), stem cell transplantation (SCT; 3%), or supportive care (26%). Median survival from the date of blastic transformation wa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tam, Constantine S., Nussenzveig, Roberto M., Popat, Uday, Bueso-Ramos, Carlos E., Thomas, Deborah A., Cortes, Jorge A., Champlin, Richard E., Ciurea, Stefan E., Manshouri, Taghi, Pierce, Sherry M., Kantarjian, Hagop M., Verstovsek, Srdan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518875/
https://ncbi.nlm.nih.gov/pubmed/18566326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-138230
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak